Biotech and pharma differ primarily in how they make their drugs. Traditional pharmaceutical companies create small molecule drugs through chemical synthesis, producing well-defined compounds that can be manufactured in large, uniform batches. Biotechnology companies use living organisms like bacteria, yeast, or mammalian cells to produce complex biological drugs known as biologics, which include monoclonal antibodies, vaccines, and gene therapies.
That core scientific distinction ripples outward into nearly every aspect of how these two industries operate, from manufacturing and storage to regulation, patents, and cost.
How the Products Are Made
Chemical synthesis, the foundation of traditional pharma, involves controlled chemical reactions across multiple steps to produce a specific compound. The process is well understood and relatively straightforward to replicate. A typical manufacturing process for a small molecule drug involves around 40 to 50 critical quality tests before a batch is released.
Biological synthesis is a different world entirely. Living cells are cultured in specialized fermentation systems to produce large, complex molecules. These molecules are extremely sensitive to temperature, light, shear forces, and enzymatic activity. Because the production depends on living systems, the final product is often heterogeneous, meaning each batch contains slight natural variations in the molecules present. A typical biologics manufacturing process requires 250 or more critical tests per batch.
Scaling up biologics from laboratory quantities to commercial production is one of the biggest challenges in the industry. Maintaining product purity and batch-to-batch consistency gets harder as volumes increase. Building and validating new biologics facilities is disproportionately expensive and time-consuming compared to small molecule plants. Even small changes to a biologics manufacturing process can alter the final product in ways that don’t apply to chemical drugs.
Storage and How Patients Receive Them
Most small molecule drugs are stable at room temperature. They tolerate heat, agitation, and even accidental freezing without losing effectiveness. If a liquid preparation freezes and thaws, it can usually still be used.
Biologics are fragile. Most must be kept refrigerated between 2°C and 8°C from the moment they’re manufactured until they reach the patient. Some require deep-freeze storage as cold as negative 60°C to negative 80°C. If a biologic accidentally freezes (when it’s not supposed to), it typically cannot be used after thawing. This cold chain requirement demands expensive infrastructure at every step of distribution.
The delivery method also differs. Small molecule drugs are often taken as pills or capsules. Biologics, because of their size and complexity, are usually injected or infused. Many biologics for chronic conditions like diabetes and rheumatoid arthritis are designed for self-injection at home, but they still require careful temperature handling during shipping.
Different Regulatory Pathways
The FDA uses separate approval tracks for each type of product. Small molecule drugs go through a New Drug Application (NDA), which requires data on chemistry, pharmacology, clinical effectiveness, and statistics. Biologics require a Biologics License Application (BLA), submitted under the Public Health Service Act. The BLA includes detailed information on manufacturing processes specifically because those processes so directly affect the final product. Approval grants the manufacturer a license to market the biologic.
This distinction matters because it shapes everything downstream, including how competitors eventually enter the market.
Generics vs. Biosimilars
When a small molecule drug’s patent expires, competitors can make a generic version. Because the active ingredient is a defined chemical compound, generics are essentially identical copies. Generic development typically costs around $3 million and takes about 3 years. Manufacturers don’t need to run lengthy clinical trials because the molecule is the same.
Copying a biologic is far more difficult. Because biologics are produced by living systems and are inherently complex, competitors can only make “biosimilars,” products that are highly similar but not identical to the original. Biosimilar development costs over $150 million and takes more than 8 years, including phase 3 clinical trials lasting around 4.6 years to demonstrate comparable safety and effectiveness.
The patent landscape also plays out differently. Generic drug makers can file for approval and begin patent litigation well before the original patent expires, positioning themselves to launch close to the expiration date. Biosimilar developers can’t start their process until the original biologic is already FDA-approved, and they must complete lengthy trials before initiating patent challenges. The result: biosimilars typically reach the market about 2.5 years after the primary patent expires, while generics often launch right when the patent clock runs out. This delay gives brand-name biologics a longer period of market exclusivity.
Business Structure and Risk
Traditional pharmaceutical companies tend to be large, established corporations with deep resources, diversified product portfolios, and global manufacturing and distribution networks. Their revenue often comes from a broad base of marketed products, which provides stability even when individual drugs lose patent protection.
Biotech companies, particularly startups, operate with a very different risk profile. Many are built around a single technology platform or a small number of drug candidates. They rely heavily on venture capital, public offerings, and partnership deals with larger companies to fund research. A biotech startup might spend years and hundreds of millions of dollars developing a product with no guarantee of approval. The upside is significant flexibility and faster decision-making. The downside is that a single failed clinical trial can threaten the company’s existence.
This dynamic creates a natural relationship between the two sectors. Large pharma companies frequently acquire or partner with smaller biotech firms to access innovative therapies, while biotech companies benefit from pharma’s manufacturing capacity, regulatory expertise, and commercial reach.
The Line Is Blurring
In practice, the boundary between biotech and pharma has become increasingly fuzzy. Most major pharmaceutical companies now have significant biologics in their pipelines. Companies like Pfizer, Roche, and Johnson & Johnson develop both small molecule drugs and biologics. The industry increasingly uses the term “biopharma” to describe companies that span both approaches.
Still, the underlying science remains distinct. A small molecule drug and a biologic face fundamentally different challenges in development, manufacturing, regulation, and competition. Understanding which category a treatment falls into gives you a practical sense of why it costs what it does, why it’s administered the way it is, and what happens when its patent protection runs out.